Fact.MR, Dubai: As per a study by Fact.MR, the global primary cell culture market is anticipated to expand at a growth rate of 11.6% CAGR over the forecast period, starting from 2021 to 2031.
Ongoing research on tissue culture and tissue engineering to develop novel therapeutics spurring the demand for primary cell culture
Fact.MR, Dubai: As per a study by Fact.MR, the global primary cell culture market is anticipated to expand at a growth rate of 11.6% CAGR over the forecast period, starting from 2021 to 2031. The market growth can be attributed to the rising prevalence of diabetes mellitus, cancer, cardiovascular diseases, autoimmune diseases, and nephrological diseases. This has resulted in increasing research and facilitating the high adoption of primary cell cultures.
According to Globocan, over 19,292,789 cases of cancer and around 9,958,133 deaths were recorded in the year 2020 due to cancers. This rapid growth in the incidence of cancer will result in increasing demand for novel therapeutics across the globe, thus, creating a lucrative growth opportunity for the primary cell culture market over the forecast period.
In 2020, around 71.0 million people are suffering from chronic hepatitis C infection, globally, according to the World Health Organization (WHO). The demand for effective treatment to curb the rising incidences of chronic disorders will drive the growth of the primary cell culture market.
Companies operating in the market are launching new products for primary cell cultures to expand their product portfolio. For instance, Lonza, a Swiss multinational chemicals and biotechnology company, launched new customizable and high-quality cryo-preserved Leukopaks in January 2021. Thus, the introduction of these novel primary cell cultures products is anticipated to drive the market growth.
“Leading market players are investing in R&D for understanding the new variants of coronavirus with the application of primary cell culture. Besides this, they are increasingly using primary cell culture for developing an effective vaccine against COVID-19 virus. Such initiatives spurred demand in the market amid pandemic,” said a Fact.MR analyst.
Key Takeaways
- The U.S. is leading the primary cell cultures market with the largest revenue share in 2020 owing to the rising incidence of chronic diseases.
- Presence of leading biopharmaceutical companies and increasing government investment in cell culture research and drug developments have bolstered the market growth in the U.K.
- Asia Pacific is estimated to emerge as the fastest-growing market for primary cell culture on the back of low costs of stem cell transplantation in the region.
- The reagents and supplements segment accounts for the largest revenue share due to increasing application for maintaining primary cell viability.
- Vaccine production is dominating the application segment owing to the increasing focus on the development of COVID-19 vaccines.
Key Drivers
- Increasing research for developing novel therapeutics will fuel the demand for primary cell culture.
- Rising prevalence of cancer, autoimmune diseases, chronic infections, and diabetes mellitus will spur the sales of primary cell culture.
- Growing focus on understanding biological processes and molecular mechanisms of the cell will drive the market growth.
- The coronavirus outbreak has resulted in boosting the demand for primary cell culture.
Key Restraints
- Lack of highly optimized culture conditions restrains the growth of primary cell culture.
- High cost of primary cell culture is hampering the demand for primary cell culture.
- Lack of expertise and skill is affecting the growth of the market negatively.
Explore tables and figures of the study. Request ToC of the report at
https://www.factmr.com/connectus/sample?flag=T&rep_id=6253
Competitive Landscape
Leading manufacturers and suppliers of primary cell culture include profiled by Fact.MR includes Merck KGaA, Danaher, Thermo Fisher Scientific Inc., Lonza, Corning Incorporated, PromoCell GmbH, FUJIFILM, Irvine Scientific Inc., Axol Bioscience Ltd., Mattek, STEMCELL Technologies Inc., HiMedia Laboratories Pvt Ltd, and ATCC. Key players operating in the market are engaging in strategic collaborations and acquisition to maintain their position in the global market.
- Thermo Fisher Scientific Inc. announced it’s collaborated with Lyell Immunopharma to develop more effective cell therapies for cancer patients.
- In 2020, Charles River Laboratories acquired HemaCare Corporation to help expanding Charles River’s capabilities in the high-growth cell therapy sector.
- In 2020, BioIVT, the U.S. based company, introduced high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development.
More Insights on the Primary Cell Culture Market
Fact.MR offers unbiased analysis of the primary cell culture market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (primary cells, reagents & supplements, and media), application (tissue culture & tissue engineering, vaccine production, gene therapy and regenerative medicine, virology, stem cell therapy, and others), end user (life science research companies and research institutes), across seven regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).
Explore Fact.MR’s Coverage on the Healthcare Domain
Cancer Therapeutics Market- Cancer incidence is still on the rise around the world. A wide range of innovative cancer therapies are being developed in light of the biological diversity of cancer and the deteriorating therapeutic values of existing cancer treatments due to drug resistance.
Drug Discovery Services Market- The expansion of drug discovery services can be attributed to an increase in research and development efforts and expenditures, as well as leading pharmaceutical companies' shift to outsourcing. The use of improved technology in the drug discovery process is also a major market growth factor. With stringent regulations in some regions on drug discovery services, high cost involved in the discovery of drug and development and usage of animals in testing are hampering the market growth.
Diabetes Diagnostics Market- In a recent analysis, Fact.MR predicted that hospital demand would continue to rise over the prediction period of 2020 to 2030. Government investment for hospitals will help to expand the market overall by making healthcare more accessible in remote areas. Through 2030, the global diabetes diagnostics market will be dominated by players from North America, Asia Pacific, and Europe.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR